Deep Track discloses 7.34% Century Therapeutics (NASDAQ: IPSC) stake on 13G

Rhea-AI Filing Summary

Century Therapeutics, Inc. received a Schedule 13G reporting that Deep Track Capital and related entities beneficially own 13,486,400 shares of its common stock, representing 7.34% of the class. The filing aggregates positions held by Deep Track Capital, LP, Deep Track Biotechnology Master Fund, Ltd., Deep Track Special Opportunities Fund, LP, and individual reporting person David Kroin, all with shared voting and dispositive power over these shares.

The ownership calculation is based on 183,685,512 shares, including common stock outstanding and additional common stock issued, plus 4,347,826 shares underlying warrants that are subject to a 9.99% beneficial ownership limitation. The reporting persons state that the securities were not acquired and are not held for the purpose of changing or influencing control of Century Therapeutics.

Insights

Institutional ownership and governance analyst

Deep Track discloses a passive 7.34% stake in Century Therapeutics.

The filing shows Deep Track Capital and affiliated funds, together with David Kroin, reporting beneficial ownership of 13,486,400 Century Therapeutics common shares, equal to 7.34% of the class. Voting and dispositive power over these shares is reported as shared rather than sole, which is typical for a manager and its advised funds.

The ownership percentage is calculated using 183,685,512 shares, combining common stock outstanding as of November 1, 2025, additional common stock issued per an January 8, 2026 filing, and 4,347,826 shares issuable from warrants. Those warrants are subject to a 9.99% Maximum Percentage that limits how many shares can be beneficially owned after exercise.

The reporting persons certify that the position is not held for the purpose of changing or influencing control of Century Therapeutics, aligning this as a passive institutional stake under Schedule 13G. Future company filings may update these ownership levels if Deep Track’s holdings or the share count change.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 01/15/2026 - 04:13 PM Learn about SEC filing dates

FAQ

What stake in Century Therapeutics (IPSC) does Deep Track report on this Schedule 13G?

Deep Track Capital and related reporting persons disclose beneficial ownership of 13,486,400 shares of Century Therapeutics common stock, representing 7.34% of the outstanding class.

Who are the reporting persons on the Century Therapeutics (IPSC) Schedule 13G?

The reporting persons are Deep Track Capital, LP, Deep Track Biotechnology Master Fund, Ltd., Deep Track Special Opportunities Fund, LP, and David Kroin.

How is the 7.34% beneficial ownership in Century Therapeutics (IPSC) calculated?

The percentage is based on 183,685,512 shares, combining 87,307,091 common shares outstanding as of November 1, 2025, 92,030,595 additional common shares issued, and 4,347,826 common shares issuable from warrants.

What warrants related to Century Therapeutics (IPSC) are included in Deep Track’s beneficial ownership?

The beneficial ownership includes 4,347,826 warrants exercisable into common stock, all subject to a 9.99% Maximum Percentage that limits beneficial ownership after any exercise.

How much of Century Therapeutics (IPSC) does Deep Track Biotechnology Master Fund, Ltd. hold?

Deep Track Biotechnology Master Fund, Ltd. reports beneficial ownership of 10,609,008 Century Therapeutics shares, equal to 5.78% of the company’s common stock.

Is Deep Track’s position in Century Therapeutics (IPSC) intended to influence control of the company?

The reporting persons certify that the securities were not acquired and are not held for the purpose of changing or influencing control of Century Therapeutics, consistent with a passive Schedule 13G filing.

What ownership limitation applies to Deep Track’s Century Therapeutics (IPSC) warrants?

The issuer will not effect warrant exercises that would cause the holders to collectively beneficially own more than 9.99% of Century Therapeutics’ outstanding common stock immediately after exercise.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

Century Therapeutics, Inc.

(Name of Issuer)

Common Stock, par value $0.0001 per share

(Title of Class of Securities)

15673T100

(CUSIP Number)

01/08/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. 15673T100

1

Names of Reporting Persons

Deep Track Capital, LP

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 13,486,400.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 13,486,400.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

13,486,400.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

7.34 %

12

Type of Reporting Person (See Instructions)

IA, OO

SCHEDULE 13G

CUSIP No. 15673T100

1

Names of Reporting Persons

Deep Track Biotechnology Master Fund, Ltd.

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

CAYMAN ISLANDS

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 10,609,008.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 10,609,008.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

10,609,008.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

5.78 %

12

Type of Reporting Person (See Instructions)

CO

SCHEDULE 13G

CUSIP No. 15673T100

1

Names of Reporting Persons

David Kroin

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 13,486,400.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 13,486,400.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

13,486,400.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

7.34 %

12

Type of Reporting Person (See Instructions)

HC, IN

SCHEDULE 13G

CUSIP No. 15673T100

1

Names of Reporting Persons

Deep Track Special Opportunities Fund, LP.

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 2,877,392.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 2,877,392.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

2,877,392.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

1.57 %

12

Type of Reporting Person (See Instructions)

PN

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Century Therapeutics, Inc.
(b)	Address of issuer's principal executive offices: 25 N. 38th Street, 11th Floor, Philadelphia, PA 19104
Item 2.
(a)	Name of person filing: (i) Deep Track Capital, LP (ii) Deep Track Biotechnology Master Fund, Ltd. (iii) David Kroin (iv) Deep Track Special Opportunities Fund, LP.
(b)	Address or principal business office or, if none, residence: (i) 200 Greenwich Ave, 3rd Floor, Greenwich, CT 06830 (ii) c/o Walkers Corporate Limited, 190 Elgin Ave, George Town, KY1-9001, Cayman Islands (iii) c/o Deep Track Capital, LP, 200 Greenwich Ave, 3rd Floor, Greenwich, CT 06830 (iv) c/o Deep Track Capital, LP, 200 Greenwich Avenue, Greenwich, CT 06830
(c)	Citizenship: (i) Delaware (ii) Cayman Islands (iii) United States (iv) Delaware
(d)	Title of class of securities: Common Stock, par value $0.0001 per share
(e)	CUSIP No.: 15673T100
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: 13,486,400
(b)	Percent of class: 7.34%
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 0
	(ii) Shared power to vote or to direct the vote: 13,486,400
	(iii) Sole power to dispose or to direct the disposition of: 0
	(iv) Shared power to dispose or to direct the disposition of: 13,486,400
Item 5.	Ownership of 5 Percent or Less of a Class.
	Not Applicable
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary. Deep Track Capital, LP is the relevant entity for which David Kroin may be considered a control person.
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Deep Track Capital, LP

Signature:	/s/ David Kroin
Name/Title:	David Kroin, Managing Member of the General Partner of the Investment Adviser
Date:	01/15/2026

Deep Track Biotechnology Master Fund, Ltd.

Signature:	/s/ David Kroin
Name/Title:	David Kroin, Director
Date:	01/15/2026

David Kroin

Signature:	/s/ David Kroin
Name/Title:	David Kroin
Date:	01/15/2026

Deep Track Special Opportunities Fund, LP.

Signature:	/s/ David Kroin
Name/Title:	David Kroin, Managing Member of the General Partner of the Investment Adviser of Deep Track Special Opportunities Fund, LP
Date:	01/15/2026

Exhibit Information

Item 4: Information with respect to the Reporting Persons' ownership of the Common Stock as of January 15, 2026, is incorporated by reference to items (5) - (9) and (11) of the cover page of the respective Reporting Person. The amount beneficially owned by each Reporting Person is determined using 183,685,512 shares, calculated using 87,307,091 Common Stock outstanding as of November 1, 2025, according to the 10-Q filed with the SEC on November 13, 2025 and 92,030,595 Common Stock issued according to the issuer's 8-K filed with the SEC on January 8, 2026 and 4,347,826 Common Stock that would be converted to Common Stock by the Reporting Person up to the Maximum Percentage. The beneficially owned shares include 4,347,826 Warrants exercisable to common stock, subject to a 9.99% Maximum Percentage exercise limitation. The Issuer shall not effect the exercise of any portion of the Warrants, to the extent that after giving effect to such exercise, the holder collectively would beneficially own in excess of 9.99% (the "Maximum Percentage") of the number of Common Stock outstanding immediately after giving effect to such exercise. Deep Track Capital LP and David Kroin may be deemed to be considered beneficial owners of a combined 9,138,574 common stock and 4,347,826 warrants subject to the Maximum Percentage exercise limitation. Deep Track Biotechnology Master Fund Ltd is the beneficial owner of a combined 7,220,313 common shares and 3,388,695 warrants subject to the Maximum Percentage exercise limitation. Deep Track Special Opportunities Fund LP is the beneficial owner of 1,918,261 common shares and 959,131 warrants subject to the Maximum Percentage exercise limitation. JOINT FILING STATEMENT PURSUANT TO RULE 13d-1(k) The undersigned acknowledge and agree that the foregoing statement on SCHEDULE 13G, is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on SCHEDULE 13G, shall be filed on behalf of each of the undersigned without the necessity of filing additional joint acquisition statements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning him or it contained therein, but shall not be responsible for the completeness and accuracy of the information concerning the others, except to the extent that he or it knows or has reason to believe that such information is inaccurate. Dated: January 15, 2026 Deep Track Capital, LP By: /s/ David Kroin David Kroin, Managing Member of the General Partner of the Investment Adviser Deep Track Biotechnology Master Fund, Ltd. By: /s/ David Kroin David Kroin, Director David Kroin By: /s/ David Kroin David Kroin Deep Track Special Opportunities Fund, LP. By: /s/ David Kroin David Kroin, Managing Member of the General Partner of the Investment Adviser of Deep Track Special Opportunities Fund, LP